These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 37475172)

  • 1. [Impact of voxelotor on hemoglobin electrophoretic and chromatographic profiles].
    Fellahi S; Mouri N; Giraud B; Martino S; de Luna G; Sakka M; Joly P; Bastard JP; Galacteros F; Moutereau S
    Ann Biol Clin (Paris); 2023 Jul; 81(3):320-326. PubMed ID: 37475172
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Voxelotor Treatment Interferes With Quantitative and Qualitative Hemoglobin Variant Analysis in Multiple Sickle Cell Disease Genotypes.
    Rutherford-Parker NJ; Campbell ST; Colby JM; Shajani-Yi Z
    Am J Clin Pathol; 2020 Oct; 154(5):627-634. PubMed ID: 32561909
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Doping control approach: Identification of equine in vitro metabolites of voxelotor (GBT440), a hemoglobin S polymerization inhibitor.
    Subhahar MB; Karakka Kal AK; Philip M; Muhammed Ajeebsanu M; Karatt TK; Perwad Z
    Rapid Commun Mass Spectrom; 2024 Jan; 38(2):e9671. PubMed ID: 38124165
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease.
    Vichinsky E; Hoppe CC; Ataga KI; Ware RE; Nduba V; El-Beshlawy A; Hassab H; Achebe MM; Alkindi S; Brown RC; Diuguid DL; Telfer P; Tsitsikas DA; Elghandour A; Gordeuk VR; Kanter J; Abboud MR; Lehrer-Graiwer J; Tonda M; Intondi A; Tong B; Howard J;
    N Engl J Med; 2019 Aug; 381(6):509-519. PubMed ID: 31199090
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systematic Review of Voxelotor: A First-in-Class Sickle Hemoglobin Polymerization Inhibitor for Management of Sickle Cell Disease.
    Han J; Saraf SL; Gordeuk VR
    Pharmacotherapy; 2020 Jun; 40(6):525-534. PubMed ID: 32343424
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Voxelotor does not inhibit sickle hemoglobin fiber formation upon complete deoxygenation.
    Worth EH; Fugate MK; Ferrone FA
    Biophys J; 2023 Jul; 122(13):2782-2790. PubMed ID: 37270670
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Model-informed drug development of voxelotor in sickle cell disease: Exposure-response analysis to support dosing and confirm mechanism of action.
    Green ML; Savic RM; Tonda M; Jorga K; Washington CB
    CPT Pharmacometrics Syst Pharmacol; 2022 Jun; 11(6):698-710. PubMed ID: 35447017
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interactions of an Anti-Sickling Drug with Hemoglobin in Red Blood Cells from a Patient with Sickle Cell Anemia.
    Strader MB; Liang H; Meng F; Harper J; Ostrowski DA; Henry ER; Shet AS; Eaton WA; Thein SL; Alayash AI
    Bioconjug Chem; 2019 Mar; 30(3):568-571. PubMed ID: 30794381
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hb S (
    Tsitsikas DA; Kamal M; Braimoh A; Benson S; Abukar J
    Hemoglobin; 2021 Nov; 45(6):355-357. PubMed ID: 33622152
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Voxelotor for the treatment of sickle cell disease in pediatric patients.
    Brown C; Tonda M; Abboud MR
    Expert Rev Hematol; 2022 Jun; 15(6):485-492. PubMed ID: 35671094
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Voxelotor (GBT440), a first-in-class hemoglobin oxygen-affinity modulator, has promising and reassuring preclinical and clinical data.
    Estepp JH
    Am J Hematol; 2018 Mar; 93(3):326-329. PubMed ID: 29352729
    [No Abstract]   [Full Text] [Related]  

  • 12. Pharmacokinetics and pharmacodynamics of voxelotor (GBT440) in healthy adults and patients with sickle cell disease.
    Hutchaleelaha A; Patel M; Washington C; Siu V; Allen E; Oksenberg D; Gretler DD; Mant T; Lehrer-Graiwer J
    Br J Clin Pharmacol; 2019 Jun; 85(6):1290-1302. PubMed ID: 30743314
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Voxelotor in adolescents and adults with sickle cell disease (HOPE): long-term follow-up results of an international, randomised, double-blind, placebo-controlled, phase 3 trial.
    Howard J; Ataga KI; Brown RC; Achebe M; Nduba V; El-Beshlawy A; Hassab H; Agodoa I; Tonda M; Gray S; Lehrer-Graiwer J; Vichinsky E
    Lancet Haematol; 2021 May; 8(5):e323-e333. PubMed ID: 33838113
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GBT440 increases haemoglobin oxygen affinity, reduces sickling and prolongs RBC half-life in a murine model of sickle cell disease.
    Oksenberg D; Dufu K; Patel MP; Chuang C; Li Z; Xu Q; Silva-Garcia A; Zhou C; Hutchaleelaha A; Patskovska L; Patskovsky Y; Almo SC; Sinha U; Metcalf BW; Archer DR
    Br J Haematol; 2016 Oct; 175(1):141-53. PubMed ID: 27378309
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase 1/2 ascending dose study and open-label extension study of voxelotor in patients with sickle cell disease.
    Howard J; Hemmaway CJ; Telfer P; Layton DM; Porter J; Awogbade M; Mant T; Gretler DD; Dufu K; Hutchaleelaha A; Patel M; Siu V; Dixon S; Landsman N; Tonda M; Lehrer-Graiwer J
    Blood; 2019 Apr; 133(17):1865-1875. PubMed ID: 30655275
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New developments in anti-sickling agents: can drugs directly prevent the polymerization of sickle haemoglobin in vivo?
    Oder E; Safo MK; Abdulmalik O; Kato GJ
    Br J Haematol; 2016 Oct; 175(1):24-30. PubMed ID: 27605087
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of sickle cell disease by increasing oxygen affinity of hemoglobin.
    Henry ER; Metaferia B; Li Q; Harper J; Best RB; Glass KE; Cellmer T; Dunkelberger EB; Conrey A; Thein SL; Bunn HF; Eaton WA
    Blood; 2021 Sep; 138(13):1172-1181. PubMed ID: 34197597
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Voxelotor for the Treatment of Sickle Cell Disease.
    Fantasia HC; Morse BL
    Nurs Womens Health; 2020 Jun; 24(3):233-237. PubMed ID: 32387142
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GBT440 improves red blood cell deformability and reduces viscosity of sickle cell blood under deoxygenated conditions.
    Dufu K; Patel M; Oksenberg D; Cabrales P
    Clin Hemorheol Microcirc; 2018; 70(1):95-105. PubMed ID: 29660913
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acute venous thromboembolism after initiation of voxelotor for treatment of sickle cell disease.
    Lemon N; Sterk E; Rech MA
    Am J Emerg Med; 2022 May; 55():225.e1-225.e3. PubMed ID: 34991907
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.